IONS Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc.'s Price-to-Sales (P/S) ratio of 13.4x is currently in line with the Biotech industry median, despite the company's recent revenue growth being less than most peers and its future revenue forecast being weaker. Analysts predict 20% annual revenue growth for Ionis over the next three years, significantly below the industry's projected 120% growth. This discrepancy suggests investors might be overvaluing the stock, potentially leading to future disappointment if the P/S ratio adjusts to better reflect its growth outlook.

Capricorn Fund Managers Ltd acquired a new position of 162,800 shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, representing a significant portion of its investment portfolio. Despite insider selling totaling approximately $35.7 million, analysts maintain a "Moderate Buy" rating with a consensus target price of $86.19 for IONS. Ionis Pharmaceuticals, a biotechnology company focused on RNA-targeted therapies, exceeded earnings estimates in its last report.

Ionis Pharmaceuticals (NASDAQ:IONS) has received a "Moderate Buy" consensus rating from 22 analysts, with an average one-year target price of $86.19. The company's stock shows strong performance, trading near recent highs with a market cap of $13.0 billion, and has seen several recent price-target upgrades. Despite beating Q3 EPS and revenue estimates, Ionis remains unprofitable, while institutional investors hold a significant stake and insiders have recently sold shares.

Assenagon Asset Management S.A. dramatically increased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 1,669% in the third quarter, acquiring 294,643 additional shares to hold a total of 312,297 shares valued at approximately $20.43 million. Despite this significant institutional buying, company insiders sold off a substantial amount of stock, totaling about 504,866 shares worth roughly $35.7 million during the last quarter. Wall Street analysts maintain a "Moderate Buy" consensus rating for Ionis, with an average price target of $86.19, and several firms have raised their price objectives and issued positive ratings.

RBC Capital has reaffirmed its Outperform recommendation for Ionis Pharmaceuticals (IONS). The average one-year price target is $85.60, suggesting an 11.06% upside from its current price, with projected annual revenue of $990MM, a 2.38% increase. Funds and institutions show a bullish outlook with a put/call ratio of 0.57 and several major holders increasing their portfolio allocations in IONS.

RBC Capital has maintained its 'Outperform' rating on Ionis Pharmaceuticals (IONS) and significantly increased its price target from $82 to $95, reflecting strong confidence in the company's future. This move aligns with a trend of consistent price target raises from various analysts, signaling positive sentiment and growth potential for the leading developer of antisense technology. Ionis Pharmaceuticals has brought several novel drugs to market and has an average analyst target price of $84.42, implying an upside from its current price.